Malik Fady Ibraham 4

What Happened

• Malik Fady Ibraham, EVP Research & Development at Cytokinetics, exercised options to acquire 3,500 shares at a $7.80 strike ($27,300 total) and immediately sold 3,500 shares in an open-market transaction at $79.51 each for $278,285 on 2026-06-23.
• The filing also lists a derivative disposition of 3,500 shares at $0, which typically reflects net settlement or option cancellation/tax withholding related to the exercise. Net proceeds before taxes and fees are roughly $250,985 (sale proceeds less exercise cost).

Key Details

• Transaction date: 2026-06-23
• Exercise (code M): 3,500 shares acquired @ $7.80 = $27,300
• Open-market sale (code S): 3,500 shares sold @ $79.51 = $278,285
• Derivative disposition (code M): 3,500 shares disposed @ $0 (likely net settlement/tax withholding)
• Shares owned after transaction: Not reported in this Form 4
• Filing timeliness: Report filed same day (2026-06-23); not marked late

Context

• This is an option exercise followed by an immediate sale (a common cashless exercise pattern): the insider exercised stock options, realized shares, and sold shares into the market. Such transactions often reflect routine option exercises and liquidity needs rather than a directional bet on the stock.
• Amounts shown are pre-tax and do not reflect commissions or withholding.